Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 37 bp deletion in exon 2 and Insertion of the selection cassette in exon 2.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CYP1B1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CYP1B1 also known as cytochrome P450 1B1 is a member of the cytochrome P450 superfamily of enzymes. This monoxygenase enzyme with a molecular mass of approximately 60 kDa plays a role in the metabolism of xenobiotics and endogenous compounds. It is mainly expressed in various tissues including the liver lungs and the artery walls. The enzyme catalyzes the hydroxylation of aromatic hydrocarbons aiding in their detoxification and removal from the body.
Biological function summary
CYP1B1 contributes to the metabolism of various drugs and toxins helping to maintain cellular homeostasis. This enzyme also participates in the conversion of steroids and fatty acids impacting hormonal regulation and fatty acid balance. While CYP1B1 does not form a specific complex it functions within the cytochrome P450 enzyme system which collectively metabolizes numerous compounds. This functional integration within a broad enzymatic network highlights its role in chemical transformation processes.
Pathways
CYP1B1 serves an essential role in the Phase I drug metabolism pathway. This pathway includes the functionalization of xenobiotic substances to prepare them for Phase II reactions. The enzyme is involved in the hydroxylation of substrates which are important steps in both the AhR and chemical carcinogenesis pathways. CYP1B1 interacts with other cytochrome P450 family members such as CYP1A1 which further facilitates the detoxification and clearance of harmful compounds from the body.
CYP1B1 is significantly associated with primary congenital glaucoma and various cancers such as breast cancer. In these conditions altered CYP1B1 activity can lead to atypical metabolism of endogenous hormones contributing to disease progression. CYP1B1's interaction with cyclin D1 is noted in cancer pathogenesis where dysregulation of cell cycle progression occurs. Therefore understanding CYP1B1's expression and function can provide insights into therapeutic strategies targeting these disorders.
